Ambeed.cn

首页 / / / / AVN-944

AVN-944 {[allProObj[0].p_purity_real_show]}

货号:A428299 同义名: VX-944 Ambeed 开学季,买赠积分,赢豪礼

AVN-944 is a selective, noncompetitive inhibitor of the enzyme directed against human IMPDH with Ki of 6-10 nM for IMPDH1/IMPDH2.

AVN-944 化学结构 CAS号:297730-17-7
AVN-944 化学结构
CAS号:297730-17-7
AVN-944 3D分子结构
CAS号:297730-17-7
AVN-944 化学结构 CAS号:297730-17-7
AVN-944 3D分子结构 CAS号:297730-17-7
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

AVN-944 纯度/质量文件 产品仅供科研

货号:A428299 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

JACS Au, 2024. Ambeed. [ A148168 ]
JMC, 2024. Ambeed. [ A187643 ]
JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]
Biomacromolecules, 2024. Ambeed. [ A110759 ]
Biomacromolecules, 2024. Ambeed. [ A203543 ]
更多 >
产品名称 Bax Bcl-2 Bcl-B Bcl-w Bcl-xL Bfl-1 Mcl-1 其他靶点 纯度
BTSA1 {[allProObj[0].p_purity_real_show]}
HA14-1 +

Bcl-2, IC50: 9 μM

{[allProObj[0].p_purity_real_show]}
Venetoclax ++++

Bcl-2, Ki: <0.01 nM

{[allProObj[0].p_purity_real_show]}
Navitoclax {[allProObj[0].p_purity_real_show]}
Obatoclax Mesylate +++

Bcl-2, Ki: 0.22 μM

{[allProObj[0].p_purity_real_show]}
ABT-737 +++

Bcl-2, EC50: 30.3 nM

+

Bcl-B, EC50: 1.82 μM

+++

Bcl-w, EC50: 197.8 nM

+++

Bcl-xL, EC50: 78.7 nM

{[allProObj[0].p_purity_real_show]}
Gambogic Acid +

Bcl-2, IC50: 1.21 μM

Bfl-1, IC50: 1.06 μM

++

Bcl-B, IC50: 0.66 μM

++++

Bcl-w, IC50: 0.02 μM

+

Bcl-xL, IC50: 1.47 μM

+

Bfl-1, IC50: 1.06 μM

++

Mcl-1, IC50: 0.79 μM

Caspase {[allProObj[0].p_purity_real_show]}
BH3I-1 +

BH3-Bcl-xL interaction, Ki: 2.4 μM

{[allProObj[0].p_purity_real_show]}
A-1331852 ++++

Bcl-xL, Ki: <0.01 nM

{[allProObj[0].p_purity_real_show]}
A-1210477 ++++

MCL-1, IC50: 26.2 nM

{[allProObj[0].p_purity_real_show]}
Maritoclax {[allProObj[0].p_purity_real_show]}
TW-37 +++

Bcl-2, Ki: 0.29 μM

+

Bcl-xL, Ki: 1.11 μM

+++

Mcl-1, Ki: 0.26 μM

{[allProObj[0].p_purity_real_show]}
UMI-77 ++

Mcl-1, Ki: 490 nM

{[allProObj[0].p_purity_real_show]}
(R)-(-)-Gossypol acetic acid ++

Bcl-2, Ki: 0.32 μM

++

Bcl-xL, Ki: 0.48 μM

+++

Mcl-1, Ki: 0.18 μM

{[allProObj[0].p_purity_real_show]}
Sabutoclax ++

Bcl-2, IC50: 0.32 μM

Bfl-1, IC50: 0.62 μM

++

Bcl-xL, IC50: 0.31 μM

++

Bfl-1, IC50: 0.62 μM

+++

Mcl-1, IC50: 0.20 μM

{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 Capase-7 Caspase Caspase-1 Caspase-10 Caspase-2 Caspase-3 Caspase-4 Caspase-5 Caspase-6 Caspase-8 Caspase-9 其他靶点 纯度
Emricasan {[allProObj[0].p_purity_real_show]}
Z-VAD(OMe)-FMK {[allProObj[0].p_purity_real_show]}
Z-VAD-FMK {[allProObj[0].p_purity_real_show]}
Q-VD-OPh {[allProObj[0].p_purity_real_show]}
VX-765 ++++

Caspase-1, Ki: 0.8 nM

++++

Caspase-4, Ki: <0.6 nM

{[allProObj[0].p_purity_real_show]}
Ac-DEVD-CHO +++

caspase-7, Ki: 1.6 nM

+++

Caspase-1, Ki: 18 nM

+++

caspase-10, Ki: 12 nM

+

caspase-2, Ki: 1.71 μM

++++

Caspase-3, Ki: 230 pM

++

Caspase-4, Ki: 132 nM

++

caspase-5, Ki: 205 nM

+++

caspase-6, Ki: 31 nM

++++

caspase-8, Ki: 0.92 nM

++

Caspase-9, Ki: 60 nM

{[allProObj[0].p_purity_real_show]}
Z-DEVD-FMK {[allProObj[0].p_purity_real_show]}
Z-IETD-FMK {[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 DNA synthesis helicase RdRp ribonucleotide reductase tRNA synthetase YB-1 其他靶点 纯度
Fexinidazole {[allProObj[0].p_purity_real_show]}
Daptomycin {[allProObj[0].p_purity_real_show]}
Blasticidin S·HCl {[allProObj[0].p_purity_real_show]}
Metronidazole {[allProObj[0].p_purity_real_show]}
Daunorubicin HCl +++

DNA synthesis, Ki: 20 nM

{[allProObj[0].p_purity_real_show]}
Triglycidyl isocyanurate p53 {[allProObj[0].p_purity_real_show]}
Nedaplatin {[allProObj[0].p_purity_real_show]}
Bendamustine {[allProObj[0].p_purity_real_show]}
Trifluridine {[allProObj[0].p_purity_real_show]}
Robinetin {[allProObj[0].p_purity_real_show]}
Carboplatin {[allProObj[0].p_purity_real_show]}
Cidofovir {[allProObj[0].p_purity_real_show]}
Cisplatin {[allProObj[0].p_purity_real_show]}
Cytarabine ++++

DNA synthesis, IC50: 16 nM

{[allProObj[0].p_purity_real_show]}
Acelarin ++++

DNA synthesis, EC50: 0.2 nM

{[allProObj[0].p_purity_real_show]}
Oxaliplatin {[allProObj[0].p_purity_real_show]}
YK-4-279 {[allProObj[0].p_purity_real_show]}
ML216 +

BLM636-1298, IC50: 0.97 μM

BLMfull-length, IC50: 2.98 μM

{[allProObj[0].p_purity_real_show]}
RK-33 {[allProObj[0].p_purity_real_show]}
Brr2-IN-3 {[allProObj[0].p_purity_real_show]}
Phen-DC3 Trifluoromethanesulfonate {[allProObj[0].p_purity_real_show]}
Favipiravir {[allProObj[0].p_purity_real_show]}
Suramin sodium salt ++

RdRp, IC50: 0.26 μM

{[allProObj[0].p_purity_real_show]}
Clofarabine ++

Ribonucleotide reductase, IC50: 65 nM

{[allProObj[0].p_purity_real_show]}
Didox {[allProObj[0].p_purity_real_show]}
(E)-3-AP {[allProObj[0].p_purity_real_show]}
Halofuginone +++

prolyl-tRNA synthetase, Ki: 18.3nM

{[allProObj[0].p_purity_real_show]}
BC-LI-0186 +++

Leucyl-tRNA synthetase, Kd: 42.1 nM

Leucyl-tRNA synthetase, IC50: 46.11 nM

{[allProObj[0].p_purity_real_show]}
SU056 +

YB-1, IC50: 1.73 μM

{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

AVN-944 生物活性

描述 AVN-944 (also known as VX-944) is an orally active, potent, selective, noncompetitive, and specific inhibitor of IMPDH (inosine monophosphate dehydrogenase). IMPDH is an essential rate-limiting enzyme in de novo guanine nucleotide synthesis. Additionally, AVN-944 acts as an inhibitor of arenavirus RNA synthesis, blocking arenavirus infection. It exhibits broad anti-cancer activities and is applicable to research on multiple myeloma (MM) and acute myeloid leukemia (AML) [1][2][3].
体内研究

AVN-944 (Orally, at doses ranging from 0 to 150 mg/kg, twice daily) significantly prolongs the median survival time of leukemia model mice [2].

体外研究

AVN-944 inhibits the growth of human multiple myeloma (MM) cell lines in a dose-dependent manner, with concentrations ranging from 0 to 1 μM, in a 48-hour period[1].

AVN-944 (800 nM, 0-72 h) triggers apoptosis in MM cell lines via a caspase-independent pathway involving Bax/AIF/Endo G [1].

AVN-944 (0-200 nM) potentiates the cytotoxic effects of Doxorubicin and Melphalan [1].

AVN-944 suppresses the proliferation of human MV-4-11 and murine Ba/F3-Flt3-ITD-dependent cell lines, with IC50 values of 26 and 30 nM, respectively [2].

AVN-944 (0-32 μM, 48 h) exhibits potent activity against arenavirus infection at low doses (7.5 μM) with minimal cytotoxicity [3].

AVN-944 (0-6.4 μM, 48 h) does not affect the viability of peripheral blood mononuclear cells (PBMNCs) [1].

AVN-944 参考文献

[1]Zimmermann AG, et al. Inosine-5'-monophosphate dehydrogenase: regulation of expression and role in cellular proliferation and T lymphocyte activation. Prog Nucleic Acid Res Mol Biol. 1998;61:181-209.

[2]Huang M, et al. Guanine nucleotide depletion inhibits pre-ribosomal RNA synthesis and causes nucleolar disruption. Leuk Res. 2008 Jan;32(1):131-41.

[3]Floryk D, et al. Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cells. Int J Cancer. 2008 Nov 15;123(10):2294-302.

AVN-944 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.09mL

0.42mL

0.21mL

10.47mL

2.09mL

1.05mL

20.94mL

4.19mL

2.09mL

AVN-944 技术信息

CAS号297730-17-7
分子式C25H27N5O5
分子量 477.512
别名 VX-944
运输蓝冰
存储条件

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 105 mg/mL(219.89 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。